MeSH | Peripheral Vascular Diseases (D016491)

Peripheral Vascular Diseases D016491

Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Peripheral Vascular Diseases

Description

Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART. MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Subtype Terms (7)

Blue Toe Syndrome

Erythromelalgia
3 drugs (1 approved, 2 experimental)

Livedo Reticularis

May-Thurner Syndrome
4 drugs (3 approved, 1 experimental)

Peripheral Arterial Disease
178 drugs (97 approved, 81 experimental)

Phlebitis
7 drugs (5 approved, 2 experimental)

Raynaud Disease
42 drugs (20 approved, 22 experimental)

Approved Indicated Drugs (2)

nylidrin hydrochloride

Phase 4 Indicated Drugs (11)

acetylsalicylic acid (aspirin)

atorvastatin (lipitor)

cilostazol (pletal)

clopidogrel (plavix)

insulin glargine (toujeo)

insulin human (humulin)

levocarnitine (carnitor)

sodium chloride

testosterone (delatestryl)

vorapaxar (zontivity)

Phase 3 Indicated Drugs (18)

acetaminophen (tylenol)

alprostadil (prostin)

gadobenate (Multihance)

gadofosveset trisodium (ablavar)

gadopenteate dimeglumine (magnevist)

human fibrin (Tisseel)

lovastatin (mevacor)

montelukast (singulair)

propionyl l-carnitine

riferminogene pecaplasmid

ticagrelor (brilinta)

treprostinil (remodulin)

warfarin (coumadin)

Phase 2 Indicated Drugs (12)

ad2/hif-1alpha/vp16

bone marrow derived mesenchymal stem cells

daprodustat (Jesduvroq)

hemoglobin glutamer 250

hydroxyethyl starch (voluven)

paclitaxel (taxol)

Phase 1 Indicated Drugs (9)

allogeneic plx-pad cells

autologous bone marrow derived mesenchymal cells

autologous hematopoietic stem cells

autologous mesenchymal stem cells

tetrahydrobiopterin

umbilical cord mesenchymal stem cells

Other Experimental Indicated Drugs (9)

atenolol (tenormin)

dexmedetomidine (precedex)

hydrochlorothiazide (esidrix)

propofol (diprivan)

ramipril (altace)

rosuvastatin (crestor)

simvastatin (zocor)

sulodexide (Aterina)

Organization Involved with Phase 4 Indications (61)

Arteriogenesis Competence Network

Aultman Health Foundation

Barnsley Hospital

Barnsley Hospital NHS Foundation Trust

Baylor University

Bristol-Myers Squibb

British Heart Foundation

Cathay General Hospital

Changhua Christian Hospital

Chimei Medical Center

China Medical University

Chung Shan Medical University

Colorado Prevention Center

Department of Veteran Affairs

En Chu Kong Hospital

Far Eastern Memorial Hospital

Federation of Associations of Hospital Doctors on Internal Medicine (FADOI) Foundation

Government of Taiwan

Government of Thailand

Hospital Universitario Getafe

Inova Health System

I-Shou University

Janssen Pharmaceutica NV

Kaohsiung Medical University

Kuang Tien General Hospital

Ludwig Maximilians University

Mackay Medical College

Mercator MedSystems, Inc.

Monash University

National Cheng Kung University

National Heart, Lung, and Blood Institute (NHLBI)

National Taiwan University

Northwestern University

Seoul National University

Shin Kong Wu Ho-Su Memorial Hospital

Taipei Veteran General hospital

Tung's Taiching MetroHarbor Hospital

University of Alabama, Birmingham

University of Antwerp

University of Arkansas

University of Basel

University of Bern

University of Colorado

University of Colorado, Denver

University of Dundee

University of Florence

University of Florida

University of Nebraska

University of Roma La Sapienza

University of Southern California

University of Texas, San Antonio

University of Virginia

Vita-Salute University of Milano. Italy

Wake Forest University

Zhejiang University

Organization Involved with Phase 3 Indications (66)

ActivBiotics Pharma

Anand, Sonia, M.D.

Asheville Cardiology Associates

Baptist Clinical Research

Beijing Northland Biotech. Co., Ltd.

Brazilian Clinical Research Institute

Brown University

Canadian Institutes of Health Research (CIHR)

Capital Medical University

Case Western Reserve University

Dartmouth University

Dexa Medica Group

Forest Laboratories

Franziskus Hospital, Berlin

Harvard University

Health Solutions, India

Heart and Stroke Foundation of Canada

Hospital do Coracao

Human Stem Cell Institute, Russia

Jacksonville Center for Clinical Research

Jagiellonian University

Kos Pharmaceuticals

Leadiant Biosciences, Inc.

Lee's Pharmaceutical

Leiden University

McMaster University

Mitsubishi Tanabe

Nanjing Medical University

Ochsner Health System

Omrix Biopharmaceuticals, Inc.

Rhode Island Hospital

SMT KASHIBAI NAVALE MEDICAL COLLEGE

Southern Illinois University

Stiftungsklinikum Boppard

The University of Texas, Dallas

Thomas Jefferson University

Thrombolysis in Myocardial Infarction Study Group

Tokyo Medical University

Udayana University

United Therapeutics

University of Athens

University of Heidelberg

University of Manitoba

University of Massachusetts

University of Oxford

University of Patras

University of Pittsburgh

University of Rennes

University of Rochester

University of Tuebingen

University of Vienna

University of Western Ontario

Utrecht University

Western Suburban Cardiologists, Ltd.

Yonsei University

ZonMw: The Netherlands Organisation for Health Research and Development

Organization Involved with Phase 2 Indications (56)

Al-Ahliyya Amman University

AMAG Pharmaceuticals, Inc.

American Heart Association

Arca Biopharma, Inc.

BioGenCell Ltd.

Biopure Corporation

Cairo University

Chinese Academy of Medical Sciences

Chinese University of Hong Kong

CPC Clinical Research

Duke University

Emory University

Florida State University

GlaxoSmithKline

Government of Japan

Health Decisions

Iberica Co. Ltd.

Indiana University

Isfahan University

Jobst Vascular Center

Juventas Therapeutics, Inc.

Kobe University

Kyushu University

Laniado Medical Center

MultiGene Vascular Systems Ltd.

National Center for Complementary and Integrative Health (NCCIH)

National Institutes of Health (NIH)

Nissan Chemical Industries

Pennsylvania State University

Reven Pharmaceuticals, Inc.

Royan Institute

Saint-Petersburg State Medical University

Stanford University

TCA Cellular Therapy

Translational Research Informatics Center, Kobe, Hyogo, Japan

University of California, San Francisco

University of Erlangen-Nuremberg

University of Jordan

University of Lyon

University of Minnesota

University of Tehran

University of Toulouse

Vericel Corporation

Organization Involved with Phase 1 Indications (17)

Affiliated Hospital of Military Medical Sciences

Boehringer Ingelheim

Deborah Heart and Lung Center

Foxhollow Technologies

Huazhong University of Science and Technology

Humboldt University

Icahn School of Medicine at Mount Sinai

Mt. Sinai Medical Center, Miami

People's Liberation Army of China

ReNeuron Limited

South China Research Center for Stem Cell and Regenerative Medicine

Southern Medical University

University of Naples Frederico II

Venturis Therapeutics

Washington University in St. Louis

Organization Involved with Other Experimental Indications (23)

Boston University

Cambridge Theranostics Ltd

Chang Gung University

Clinical Trial Center Maastricht

Gottfried Wilhelm Leibniz Universität Hannover

Maastricht University

Midwest Cardiovascular Research Foundation

National Health and Medical Research Council, Australia

National Institute on Aging (NIA)

Reliant Pharmaceuticals

Spectranetics Corporation

St. John's Research Institute

United States Army

University of Angers

University of Brescia

University of Cambridge

University of Limerick

University of Oklahoma

University of Pennsylvania

University of Rome Tor Vergata

University of Toronto

Hierarchy Tree View

MeSH
ICD-10

UMLS Data

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.